Duloxetine (Dulo)
Duloxetine Capsule, Delayed Release
Product Images NDC 25000-609
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 25000-609). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Marksans Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Dulo-20mg-60s (Duloxetine 20mg 60s Label)
This is a description of a medication called Duloxetine in the form of delayed-release capsules. Each capsule contains 22.4 mg of duloxetine hydrochloride, equivalent to 20 mg duloxetine, and there are 60 capsules in each container. The medication guide should be provided to each patient along with the prescription. The recommended dosage is available in the literature accompanying the medication, and it should be stored at 25°C (77°F); excursions are permitted to 15° to 30°C (59° to 86°F). The medication should be contained in a tightly closed container and kept out of the reach of children. The manufacturer is Time-Cap Labs, Inc., with promotion by Marksans Pharma Ltd., located in India.*
Dulo-30mg-30s (Duloxetine 30mg 30s Label)
Dulo-30mg-90s (Duloxetine 30mg 90s Label)
This is a medication called Duloxetine in the form of delayed-release capsules. Each capsule contains 33.7mg of duloxetine hydrochloride, which is equivalent to 30mg duloxetine. The usual dosage recommendation can be found in the accompanying literature. It should be stored at room temperature (15° to 30°C) and dispensed in a tightly closed container. It is important to keep it away from children and not to use it if the inner seal is missing or broken. The medication guide is provided separately to each patient. This medication is for prescription use only. The manufacturing company is Marksans Pharma Ltd. located in Goa, India.*
Dulo-60mg-30s (Duloxetine 60mg 30s Label)
This is a medication information sheet for Duloxetine Delayed-Release Capsules, USP, with NDC number 25000-610-03. Each capsule contains 67.3 mg of duloxetine hydrochloride, equivalent to 60 mg of duloxetine. It is an Rx-only medication and should be dispensed with the Medication Guide provided to each patient. The usual dosage and storage information are provided, along with the manufacturer's details. The medication is produced by Marksans Pharma Ltd. in Goa, India, and distributed by Time-Cap Labs, Inc. in Farmingdale, NY, USA.*
Dulo-60mg-90s (Duloxetine 60mg 90s Label)
This is a prescription drug with the NDC code 25000-610-07. It contains 90 capsules of Duloxetine Delayed-Release Capsules, USP. Each capsule has 67.3 mg of Duloxetine hydrochloride, USP equivalent to 60 mg Duloxetine. The pharmacist must dispense the Medication Guide provided separately to each patient. Usual dosage and storage conditions are in the accompanying literature. It should be kept in a tightly closed container at room temperature. The drug is manufactured for Time-Cap Labs, Inc. in Farmingdale, NY, and manufactured by Marksans Pharma Ltd. in Goa, India. The mfg. Lic. No. is GO/DRUGS/515.*
Fig1 (Fig1)
The graph is displaying the time from randomization to relapse (in days) for two different treatments: placebo and duloxetine. However, additional information or context is needed to provide a more complete description.*
Fig10 (Fig10)
This text provides information on the percentage of patients improved in a study. The study compares the effects of a placebo with duloxetine, taken once daily in doses of 60-120mg. The graph shows the percentage improvement in pain from baseline. However, there is insufficient context and data to determine the full scope and results of the study.*
Fig2 (Fig2)
This is a graph that shows the proportion of patients with relapse over time (in days) after being randomized to receive either a placebo or duloxetine treatment. The x-axis shows the time from randomization to relapse in days, while the y-axis shows the percentage of patients who experienced a relapse. The graph indicates that the duloxetine treatment was more effective in preventing relapse compared to placebo.*
Fig3 (Fig3)
This document appears to be a chart displaying the percentage improvement of patients who received different doses of medications (Duoweine and Duloseine) for pain relief. The X-axis shows the different levels of improvement, ranging from 210 to 280, while the Y-axis shows the different dosages of the medications. The chart shows that patients who received Duoweine 60mg 8D had the highest percentage of improvement (100%), while patients who received Duloseine 20mg QD had the lowest percentage of improvement. It is unclear what the specific condition being treated is or when this data was collected.*
Fig4 (Fig4)
Fig5 (Fig5)
Fig6 (Fig6)
Fig8 (Fig8)
The text provides a chart of the percentage of patients who experienced pain improvement from baseline after taking either a placebo or duloxetine at a dose of 60-120 mg once daily. The chart shows the percent improvement in pain on the y-axis and a range of numbers on the x-axis. It is not clear what these numbers represent, as no context or label is provided.*
Fig9 (Fig9)
The text provides information in the form of a graph showing the improvement percentage of patients. The x-axis shows a range from 210 to 280 and the y-axis shows percentage improvement. The graph has two lines, one for the placebo and one for Duloxetine 60 mg once daily. The percentage improvement for Duloxetine is consistently higher than for the placebo. The graph relates to pain improvement from baseline (BOCF).*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
